ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer

Loredana Vecchione(Charité - Universitätsmedizin Berlin), Florian Lordick(Leipzig University), George Pentheroudakis(Hellenic Cooperative Oncology Group), Sebastian Stintzing(Humboldt-Universität zu Berlin), Jean-Yves Douillard(European Society for Medical Oncology)
ESMO Open
January 1, 2020
10.1136/esmoopen-2020-000826
Cited by 90

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Gastric cancer
|The Lancet|2020|4.8k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k